Baseline Matters: The Importance of Covariation for Baseline Severity in the Analysis of Clinical Trials

REFERENCES

• Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatment. Arch Gen Psychiatry 1989; 46:971–982.
   PubMed Web of Science ®Google Scholar
• Klein DF, Ross DC. Reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program General Effectiveness Report. Neuropsychopharmacology 1993; 8(3):241–251.
   PubMed Web of Science ®Google Scholar
• Fleiss JL. Appendix A: Sample-size determination. In Design and Analysis of Clinical Experiments. New York, NY: Wiley, 1986; 369–417.
   Google Scholar
• Alterman AI, Kampman K, Boardman CR, Cacciola JS, Rutherford MJ, McKay JR, Maany I. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug Alcohol Depend 1997; 46:79–85.
   PubMed Web of Science ®Google Scholar
• Kampman KM, Volpicelli JR, Mulvaney F, Rukstalis M, Alterman AI, Pettinati H, Weinrieb RM, O’Brien CP. Cocaine withdrawal severity and urine toxicology results from treatment entry predit outcome in medication trials for cocaine dependence. Addict Behav 2002; 27(2):251–260.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Aharonovich E, Garawi F, Levin FF, Rubin E, Raby WN, Vosburg SK, Nunes EV. Utility of lead-in period in cocaine dependence pharmacotherapy trials. Drug Alcohol Depend 2005; 77(1):7–11.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, Nunes EV. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006; 81(3):267–274.
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kranzler HT, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. J Am Med Assoc 2005; 293:1617–1625.
   PubMed Web of Science ®Google Scholar
• Stitzer ML, Petry N, Peirce J, Kirby K, Killeen T, Roll J, Hamilton J, Stabile PQ, Sterling R, Brown C, Kolodner K, Li R. Effectiveness of abstinence-based incentives: Interaction with intake stimulant test results. J Consult Clin Psychol 2007; 75:805–811.
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, O’Brien CP. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75(3):233–240.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20:1534–1541.
   PubMed Web of Science ®Google Scholar
• Pettinati HW, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcohol subtype. Alcohol Clin Exp Res 2000; 24:1041–1049.
   PubMed Web of Science ®Google Scholar
• Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 2005; 29:395–401.
   PubMed Web of Science ®Google Scholar
• Najavits LM. Seeking Safety: A Treatment Manual for PTSD and Substance Abuse. New York, NY: Guilford, 2002.
   Google Scholar
• Miller S, Pagan D, Tross S Women’s health education. In Peer Activism for Female Partners of Injection Drug Users. New York, NY: Columbia University, 1998, Unpublished treatment manual.
   Google Scholar
• Hien DA, Wells EA, Jiang H, Suarez-Morales L, Campbell AN, Cohen LR, Miele GM, Killeen T, Brigham GS, Zhang Y, Hansen C, Hodgkins C, Hatch-Maillette M, Brown C,Kulaga A, Kristman-Valente A, Chu M, Sage R,Robinson JA, Liu D, Nunes EV. Multi-site randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol 2009; 77:607–619.
   PubMed Web of Science ®Google Scholar
• Hien DA, Campbell AN, Killeen T, Hu MC, Hansen C, Jiang H, Hatch-Maillette M, Miele GM, Cohen LR, Gan W, Resko SM, Dibono M, Wells EA, Nunes EV. The impact of trauma-focused group therapy upon HIV sexual risk behaviors in the NIDA Clinical Trials Network “Women and trauma” multi-site study. AIDS Behav 2010; 14(2):421–430.
   PubMed Web of Science ®Google Scholar
• Booth RE, Watters JK, Chitwood DD. HIV risk-related sex behaviors among injection drug users, crack smokers, and injection drug users who smoke crack. Am J Public Health 1993; 83:1144–1148.
   PubMed Web of Science ®Google Scholar
• Lambert D. Zero-inflated Poisson regression with an application to defects in manufacturing. Technometrics 1992; 34:1–14.
   Web of Science ®Google Scholar
• Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems. Stat Med 2002; 21:2917–2930.
   PubMed Web of Science ®Google Scholar
• Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schultz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. J Am Med Assoc 1996; 276:637–639.
   PubMed Web of Science ®Google Scholar
• Moher D, Schulz KF, Altman D, CONSORT Group. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc 2001; 285:1987–1991.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. BMJ 2010; 340:c332.
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG, CONSORT Group. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomized trials. BMJ 2010; 340:c869.
   PubMed Web of Science ®Google Scholar
• Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other mis(uses) of baseline data in clinical trials. Lancet 2000; 355(9209):1064–1069.
   PubMed Web of Science ®Google Scholar
• Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schünemann HJ, Tornetta P, III. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res 2006; 447:247–251.
   PubMed Web of Science ®Google Scholar
• Hernández AV, Steyerberg EW, Taylor GS, Marmarou A, Habbema JD, Maas AI. Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic brain injury: A systematic review. Neurosurgery 2005; 57(6):1244–1253.
   PubMed Web of Science ®Google Scholar
• Hernández AV, Boersma E, Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: Are most of them misleading? Am Heart J 2006; 151(2):257–264.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J Am Med Assoc 1991; 266:93–98.
   PubMed Web of Science ®Google Scholar